The present invention refers to the creation of two systems the first consisting in the immediate release of the drug through the disintegration of the system the second system being a matrix which is a modified release drug support which in this particular case uses dicloxacillin as an active both matrixes forming a bilayer tablet with a drug release controlled according to the contact of the surface with the medium. The modified release system of the matrix is characterised in that it comprise...

FIELD: chemistry. ^ SUBSTANCE: present invention relates to an improved method of producing sodium salt of 6-[3-(26-dichlorophenyl)-5-methyl-isoxazole-4-carbamino]-penicillanic acid (dicloxacillin) through acylating 6-aminopenicillanic acid with acid chloride of 3-(26-dichlorophenyl)-5-methyloxazole-4-carboxylic acid with subsequent extraction of the target product from the reaction mass. Acylation is carried out in a water-acetone medium through simultaneous addition into the reaction mixture a...

The invention relates to compositions containing nanoparticles and to uses o f said compositions for encapsulating therapeutically active substances in cel ls by means of nanoparticles with a particular coating. The particles are chemically formed in such a way as to enable a high intracellular absorption into the cells. The encapsulation requires no direct binding between nanoparticles and the therapeutically active substance. The encapsulation enables an increased efficiency of the substance w...

1. Penicillin reverses resistance of mycobacterium to INH. 2. Penicillin as claimed in claim 1 can be a broad spectrum penicillin or a narrow spectrum penicillin. 3. Penicillin as claimed in claim 1 and 2 can be any single penicillin or combination of more than one penicillin. 4. Penicillin as claimed in claim 1 to 3 can have activity against beta-lactamase producing organism. 5. Penicillin as claimed in claim 1 to 3 can have activity against penicillinase producing organism. 6. Penicillin as cl...

1. The method of treating drug-resistant mycobacterial infection in an animal comprising administration to the said animal Penicillin and isoniazid (INH). 2. The method of claim 1 wherein penicillin is administered simultaneously with INH. 3. The method as claimed in claim 1 wherein penicillin and INH are administered sequentially. 4. The method as claimed in claim 1 to 3 wherein penicillin can be a broad spectrum penicillin or a narrow spectrum penicillin. 5. The method as claimed in claim 1 to...

An antibiotic product in particular a betalactam such as cephalosporin (in particular cefuroxime and/or cefpodoxime) or a penicillin (in particular axmoxicillin or dicloxacillin) is comprised of at least three dosages forms each of which has a different release profile with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment there is an immediate release dosage form as well as two or more delayed release dosage forms with each of the dosage forms ...